Platinum-containing regimens for metastatic breast cancer

Egger, Sam; Willson, Melina L; Morgan, Jenna; Walker, Harriet; Carrick, Sue; Ghersi, Davina; Wilcken, Nicholas

doi:10.1002/14651858.cd003374.pub4

Cited by 50 publications

(40 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…35 Our network meta-analysis, directly and indirectly, compared anthracycline vs C and anthracycline plus Pl vs Pl, and showed no significant improvement of pCR rates by adding anthracycline to NAT regimen. during systemic therapy for metastatic breast cancer 38 and in the neo-adjuvant setting for TNBC. 24 Our study also confirmed that Plcontaining regimens render a higher risk of febrile neutropenia and grade 3-grade 4 thrombocytopenia.…”

Section: Discussionmentioning

confidence: 99%

Neo‐adjuvant therapy for triple‐negative breast cancer: Insights from a network meta‐analysis

et al. 2020

View full text Add to dashboard Cite

Background: The best regimen of neo-adjuvant therapy for triple-negative breast cancer (TNBC) is unknown. Recent studies have shown promising data that adding carboplatin or pembrolizumab improves the rate of pathologic complete response (pCR) in TNBC. Therefore, we performed a network meta-analysis to define the overall, most effective, neo-adjuvant systemic therapy for TNBC. Methods: We searched for studies comparing different neo-adjuvant regimens in patients with TNBC. We performed a network meta-analysis comparing the regimens using the random-effects model. We focused on anthracycline, bevacizumab, pembrolizumab, and platinum salts (Pl). All study regimens contained a taxane. We analyzed the rate of pCR (ypT0/is, N0), and the incidence of febrile neutropenia, grade 3-grade 4 thrombocytopenia, nausea/vomiting, and diarrhea. Results: We identified a total of 13 randomized control trials for this analysis. We compared ten different classes of regimens. We found that regimens containing Pl were significantly superior to non-PI-containing regimens for the rate of pCR. Similarly, pembrolizumab-containing regimens were associated with significantly higher pCR rates. Regimens containing bevacizumab significantly increased the rate of pCR as well. However, it was equivocal as to whether the addition of Pl to pembrolizumab-containing regimen increases pCR rates. Adding anthracycline into the regimen did not show an improved rate of pCR. In the safety analysis, regimens containing Pl were associated with a significantly higher incidence of febrile neutropenia and grade 3-grade 4 thrombocytopenia. The regimen containing anthracycline plus bevacizumab plus Pl was associated with a higher risk of gastrointestinal adverse events. Conclusions: For TNBC, regimens containing bevacizumab, pembrolizumab, or Pl are most effective in terms of pCR rates, though it is unclear whether combining all these medications has the greatest efficacy. Additionally, the benefit of using anthracycline in the neo-adjuvant therapy regimen for TNBC is not apparent, which may warrant a further head-to-head comparison.

show abstract

Section: Discussionmentioning

confidence: 99%

Neo‐adjuvant therapy for triple‐negative breast cancer: Insights from a network meta‐analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Moreover, while it is not entirely scientifically supported, it appears conceivable that PPI may affect the body pH by buffering the stomach, that is their main target [188]. 6.3) Melatonin (MT) in breast cancer.…”

Section: ) Hydrogen Ion Dynamics In Multiple Drug Resistance (Mdr) Imentioning

confidence: 99%

“…Many associated risk factors, either genetic, from BRCA1 and BRCA2 gene mutations, plus a wide array of other genetic derangements [3], and a multiplicity of environmental factors such as as age, obesity and estrogens, among many others [4] are involved in the onset of BC. In spite of significant advances in therapy, the overall results are not too successful up to the present time, especially in advanced disease [5,6]. This may indicate that a change towards a more comprehensive and perhaps radically different perspective is necessary in order to incorporate more rational and less toxic treatments, and at the same time foster a better understanding of this multifaceted disease.…”

Section: Introductionmentioning

confidence: 99%

A New and Integral Approach to the Etiopathogenesis and Treatment of Breast Cancer based upon its Hydrogen Ion Dynamics

Harguindey¹,

Alfarouk

Orozco³

et al. 2019

Preprint

View full text Add to dashboard Cite

Despite all efforts, the treatment of breast cancer (BC) cannot be considered to be a success story. The advances in surgery, chemotherapy and radiotherapy have not been sufficient. Indeed, the accumulated experience clearly indicates that new perspectives and non-main stream approaches are needed to better characterize the etiopathogenesis and treatment of this disease. This contibution deals with how the new pH-centric anticancer paradigm plays a fundamental role in reaching a more integral understanding of the etiology, etiopathogenesis and treatment of this multifactorial disease. For the first time the armamentarium available for the treatment of the different types and phases of BC is approached here from a Unitarian perspective based upon the hydrogen ion dynamics of cancer. The wide-ranged pH-related molecular, biochemical and metabolic model is able to embrace most the fields and subfields of breast cancer pathology. This single and integrated approach allows to advance a unidirectional program to treatment. Further efforts in this line are likely to first improve the therapeutics of each subtype of this tumor, then every phase of the disease and finally every individual patient.

show abstract

“…Cisplatin, which is a metal-based anticancer drug, has been extensively used as a chemotherapy medication for various kinds of cancers such as ovarian cancer, head and neck cancer, cervical cancer, breast cancer, bladder cancer, esophageal cancer, lung cancer, brain tumors and neuroblastoma [ 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 ]. Cisplatin works by interfering with DNA replication and inhibits the growth of cancer cells [ 22 ].…”

Section: Introductionmentioning

confidence: 99%

Combinatorial Effect of Cold Atmosphere Plasma (CAP) and the Anticancer Drug Cisplatin on Oral Squamous Cell Cancer Therapy

Lee

Jeong

Kook

et al. 2020

IJMS

View full text Add to dashboard Cite

Cold atmospheric plasma (CAP) has been extensively investigated in the local treatment of cancer due to its potential of reactive oxygen species (ROS) generation in biological systems. In this study, we examined the synergistic effect of combination of CAP and cisplatin-mediated chemotherapy of oral squamous cell carcinoma (OSCC) in vitro. SCC-15 OSCC cells and human gingival fibroblasts (HGF-1) cells were treated with cisplatin, and then, the cells were irradiated with CAP. Following this, viability and apoptosis behavior of the cells were investigated. The viability of SCC-15 cells was inhibited by cisplatin with a dose-dependent manner and CAP treatment time. HGF-1 cells also showed decreased viability by treatment with cisplatin and CAP. Combination of 1 μM cisplatin plus 3 min of CAP treatment or 3 μM cisplatin plus 1 min of CAP treatment showed a synergistic anticancer effect with appropriate cytotoxicity against normal cells. ROS generation and dead cell staining were also increased by the increase in CAP treatment time. Furthermore, tumor-suppressor proteins and apoptosis-related enzymes also increased according to the treatment time of CAP. We showed the synergistic effect of cisplatin and CAP treatment against SCC-15 cells with low cytotoxicity against normal cells.

show abstract

Platinum-containing regimens for metastatic breast cancer

Abstract: Analysis 1.3. Comparison 1 Platinum vs non-platinum regimens (subgroup analysis 1: by treatment-comparisons assessing mTNBC), Outcome 3 Objective tumour response rate (assessable participants

Cited by 50 publications

References 49 publications

Neo‐adjuvant therapy for triple‐negative breast cancer: Insights from a network meta‐analysis

Neo‐adjuvant therapy for triple‐negative breast cancer: Insights from a network meta‐analysis

A New and Integral Approach to the Etiopathogenesis and Treatment of Breast Cancer based upon its Hydrogen Ion Dynamics

Combinatorial Effect of Cold Atmosphere Plasma (CAP) and the Anticancer Drug Cisplatin on Oral Squamous Cell Cancer Therapy

Contact Info

Product

Resources

About